Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST) from its SEC filings: 2025 revenue $44.5 million (-23% vs the year before), net margin -188%, free cash flow -$53.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $44.5 million |
| Revenue growth | -23% |
| Net income | -$83.8 million |
| Net margin | -188.1% |
| Free cash flow | -$53.0 million |
| Diluted EPS | $-0.78 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +38% |
| Cash | $98.5 million |
| Long-term debt | $55.0 million |
| Share count, 1 year | +26% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.